- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 80,955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Trametinib
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Head and Neck Cancer
- Interventions
- bevacizumab, docetaxel, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 6
- States / cities
- Cleveland, Ohio • Mentor, Ohio • Middleburg Heights, Ohio + 3 more
- Conditions
- Strain of Muscle and/or Tendon of Lower Leg, Fracture of Lower Leg, Crushing Injury of Lower Leg, Fracture Malunion - Ankle and/or Foot, Disorder of Joint of Ankle and/or Foot, Complete Tear, Ankle and/or Foot Ligament, Pathological Fracture - Ankle and/or Foot, Loose Body in Joint of Ankle and/or Foot
- Interventions
- Not listed
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Skin Laxity
- Interventions
- calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
- Combination Product
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Muscular Dystrophies
- Interventions
- Albuterol, Oxandrolone
- Drug
- Lead sponsor
- FDA Office of Orphan Products Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Myeloproliferative Neoplasm, Unclassifiable
- Interventions
- Not listed
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Bladder Cancer
- Interventions
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin
- Drug · Radiation · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Persona Trabecular Metal Tibia, Verasense technology, MUVR
- Device
- Lead sponsor
- Washington Hospital Healthcare System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Fremont, California
- Conditions
- IBM, Inclusion Body Myositis
- Interventions
- electrical impedance myography (EIM)
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 46 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Post-operative Pain, Gynecologic Surgery, Regional Anesthesia
- Interventions
- QL (quadratus lumborum) block administration
- Drug
- Lead sponsor
- Pedram Bral
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Brain Cancer
- Interventions
- Optune (NovoTTF-100A)
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 5 more
- Conditions
- Asthma
- Interventions
- Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product
- Drug
- Lead sponsor
- Amneal Ireland Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Brookhaven, New York
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-DOTA0-Tyr3-Octreotate
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 41
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 33 more
- Conditions
- Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis
- Interventions
- Cholic Acids
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- End Stage Renal Disease
- Interventions
- ergocalciferol supplementation, placebo
- Dietary Supplement · Other
- Lead sponsor
- Dialysis Clinic, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 12
- States / cities
- Redding, California • Albany, Georgia • Shreveport, Louisiana + 9 more
- Conditions
- Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- Lenalidomide, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 13
- States / cities
- San Diego, California • Denver, Colorado • Chicago, Illinois + 9 more
- Conditions
- Alcohol Intoxication
- Interventions
- Not listed
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lung Cancer Screening
- Interventions
- Lung Cancer Screening
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Osteoarthritis (OA) of the Knee
- Interventions
- Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Grosse Pointe Farms, Michigan
- Conditions
- Testicular Cancer
- Interventions
- Radical inguinal orchiectomy, Radical external oblique fascia sparing orchiectomy
- Procedure
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Loma Linda, California • Los Angeles, California
- Conditions
- Schizophrenia
- Interventions
- Clozapine, Olanzapine, Haloperidol
- Drug
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Orangeburg, New York
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Comprehensive Geriatric Assessment, Health Education, Medical Device Usage and Evaluation, Supportive Care
- Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Interventions
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more